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Abstract 
Pancreatic islet transplantation has been validated as a treatment for type 1 diabetes since it maintains consistent 
and sustained type 1 diabetes reversal. However, one of the major challenges in pancreatic islet transplantation is the 
body’s natural immune response to the implanted islets. Immunosuppressive drug treatment is the most popular 
immunomodulatory approach for islet graft survival. However, administration of immunosuppressive drugs gives 
rise to negative side effects, and long‑term effects are not clearly understood. A bioartificial pancreas is a therapeutic 
approach to enable pancreatic islet transplantation without or with minimal immune suppression. The bioartificial 
pancreas encapsulates the pancreatic islets in a semi‑permeable environment which protects islets from the body’s 
immune responses, while allowing the permeation of insulin, oxygen, nutrients, and waste. Many groups have 
developed various types of the bioartificial pancreas and tested their efficacy in animal models. However, the clinical 
application of the bioartificial pancreas still requires further investigation. In this review, we discuss several types of 
bioartificial pancreases and address their advantages and limitations. We also discuss recent advances in bioartificial 
pancreas applications with microfluidic or micropatterning technology.
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1  Background
Diabetes mellitus type 1, or type 1 diabetes, is a wide-
spread disease where individuals are unable to produce 
the insulin necessary to process blood glucose because 
of an autoimmune response which destroys the body’s 
insulin-producing beta cells [1]. Insulin therapy has been 
used to treat type 1 diabetes patients since the discovery 
of insulin in 1922. However, daily insulin treatments are 
not able to precisely and continuously meet the demands 
of the uncontrolled variations in stress, food intake, 
and physical activities [2]. As an alternative treatment, 
pancreatic islet transplantation has been attempted to 
maintain consistent and sustained type 1 diabetes rever-
sal. Successful pancreatic islet transplantation does not 
require rigorous blood glucose monitoring and also 
prevents the progression of diabetic complications [3]. 
However, one of the primary challenges facing pancre-
atic islet transplantation is the body’s natural immune 
response towards the foreign islets. Implantation of islets 
from donors can give rise to rapid immune response 
when exposed to the recipient immune system [4, 5]. 
Moreover, the traditional approach in which immuno-
suppressive drugs are administered during and after 
islet transplantation has been known to cause many 
side effects, such as oral ulcers, peripheral edema, ane-
mia, weight loss, and episodic diarrhea [4, 6]. Thus, 
approaches for islet transplantation therapy without use 
of immunosuppressive drugs are desired. To address this 
issue, many groups have attempted to encapsulate islets 
within bioartificial pancreases [7–9]. A bioartificial pan-
creas encapsulates the pancreatic islets in a semi-per-
meable environment and prevents islet exposure to the 
body’s immune responses while allowing the permea-
tion of insulin, oxygen, nutrients, and waste products [9]. 
Prevention of contact between the transplanted islets 
and immunocompetent cells can reduce cell-mediate 
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immunity. Several types of bioartificial pancreases have 
been investigated which utilize macro- and microencap-
sulation [9]. In addition, engineering of the islet surface 
is another immunoisolation approach in which the sur-
face of islets is modified to form an immune barrier [7]. 
Although various kinds of bioartificial pancreases have 
been developed, clinical outcomes are still not clear. 
In this review, we describe bioartificial pancreases and 
islet surface modification approaches, and address their 
advantages and limitations as immunoisolation strate-
gies. We also discuss recent advances in bioartificial pan-
creas applications with microfluidic or micropatterning 
technology.
2  Review
2.1  Macroencapsulation of pancreatic islets
Immunoisolation of pancreatic islets is generally divided 
into three different methods of encapsulation: macro-, 
micro-, and nanoencapsulation (islet surface modifica-
tion at nano-scale) (Fig.  1) [10]. Macroencapsulation is 
the transplantation of a large number of islets within an 
implantable device (either extravascular or intravascu-
lar) [11]. Transplantation sites for the macrocapsule vary 
based on the application. Extravascular macrocapsules 
are implanted intraperitoneally or subcutaneously, while 
intravascular macrocapsules are implanted around a 
vessel and exposed to systemic blood flow [11]. In this 
review, the evolution of macroencapsulation will be 
discussed based on extravascular and intravascular 
implantation.
2.1.1  Extravascular application of macroencapsulation 
device
2.1.1.1 Diffusion chamber Extravascular approaches 
of macroencapsulation began with the diffusion cham-
ber. The diffusion chamber provided an artificial bar-
rier against larger lymphocytes and macrophages, while 
allowing passage of smaller nutrients, gases, and insulin. 
One of the well-studied diffusion chamber designs is the 
TheraCyte bio-artificial pancreas (Fig. 2) [11]. The Thera-
Cyte system is made from polytetrafluoroethylene (PTFE) 
and is composed of a planar, bilaminar membranous 
pouch. The inner, cell impermeable, immunoisolation 
membrane has a pore size of 0.4 µm; the outer membrane, 
utilized for tissue engraftment, has a pore size of 5 µm [11, 
12]. The TheraCyte diffusion chamber is implanted at a 
subcutaneous site where insulin can diffuse into the blood 
through the membrane [12], while the islets are protected 
Fig. 1 Summary of encapsulation from macro‑ to nanoscale. Reused 
with permission from [10]
Fig. 2 TheraCyte diffusion chamber. Reused with permission from 
[11]
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from the host’s immune system [12]. The subcutaneous 
placement allows for ease of surgical access and retrieval 
if necessary. Additionally, the islets exist as clusters within 
the macrocapsule diffusion chamber (as in the native pan-
creas), which allows for cell-to-cell communication and 
has shown to be beneficial for insulin production from 
pancreatic beta cells.
A study was done in which rat islets were encapsulated 
in the TheraCyte device and implanted within non-obese 
diabetic (NOD) mice [13]. The implanted islets survived 
and showed response to glucose levels, maintaining suf-
ficient insulin secretion to normalize blood glucose lev-
els in hyperglycemic diabetic rats at least 50  days [13]. 
Through this result, the encapsulated rat islets within 
the TheraCyte device were shown to maintain their 
function. However, there is concern for clumping of the 
islets, which could potentially reduce oxygen and nutri-
ent flow to the interior of the islets [11]. The interior cells 
can become necrotic, which results in a significant defi-
ciency in insulin production within the diffusion cham-
ber [12]. Since islets generally need to be located within 
150–200 µm of a blood vessel, this is a common weakness 
of the extravascular implantation device [14]. This lack of 
vascularization can cause increased diffusion times for 
insulin, potentially leading to insulin inhibition within the 
islets due to a build-up of insulin in the diffusion chamber 
[11]. Thus, reduction of clumping and enhanced vascu-
larization within the device are areas of ongoing research.
Another study was conducted using a diffusion cham-
ber with a bi-laminar encapsulation device implanted 
within streptozotocin (STZ)-induced diabetic rats [15]. 
These rats all received roughly eight million MIN6 cells 
(pancreatic beta cell-line) in a xenograft macroencapsula-
tion diffusion chamber. Those rats that received the mac-
rocapsule diffusion chamber showed recovery to normal 
glycemia up to 30 weeks post transplantation, as well as 
associated weight gain [15].
2.1.1.2 Layered alginate sheets with  islets A possible 
remedy to the hypoxic environment seen in clumping 
of islet cells is immobilization of islets in layered algi-
nate sheets. Alginate is a hydrogel consisting of anionic 
polysaccharides extracted from seaweed, which confers 
excellent biocompatibility [16]. This layered technique 
inhibits clumping while allowing adequate numbers of 
islets to be implanted. The disadvantage of using alginate 
as a hydrogel is the variability associated with its pore size 
due to its sourcing from organic seaweed [11]. A recent 
study was conducted using an alginate layering device 
with porcine islets implanted into STZ-induced diabetic 
monkeys (Fig. 3) [16]. The five monkeys received three to 
five monolayer alginate devices, and they showed reversal 
of hyperglycemia for up to 28 weeks. Histological evalu-
ation of the monolayer cellular device showed little graft 
fibrosis or alginate degradation. However, CD3 stained 
lymphocytes and CD9 stained macrophages were found 
within the macrocapsule along with increased levels of 
anti-porcine antibodies shortly after implantation [16].
2.1.2  Vascular application of macroencapsulation device
2.1.2.1 Coiled hollow fiber tube The vascular approach 
to macroencapsulation offers a whole new set of advan-
tages and disadvantages. With the incorporation of the 
vascular system into the macrocapsule device, nutrients, 
oxygen, and insulin become more readily available, result-
ing in better blood glucose control [11]. However there is 
greater risk of thrombosis and fibroblast growth on the 
membrane with the closer proximity to blood flow [17]. 
In addition, the surgical procedure is more invasive and 
poses greater risks [11]. A common intravascular applica-
tion device is a hollow fiber tube contained in a housing 
connected to the host vasculature (Fig.  4) [18, 19]. The 
islets are placed inside the device and on the interior of 
the semipermeable membrane. Glucose, oxygen, nutri-
ents, and insulin can pass freely across the membrane. 
The immune barrier is retained as lymphocytes and 
immunoglobulins cannot cross the membrane, protecting 
islet viability. The longevity of this device is increased by 
the incorporation of two syringe ports in the acrylic disk-
shaped housing, which allows the addition of islets after 
surgical implantation of the device (Fig. 5) [18].
In one study, fifteen diabetic pancreatomized dogs 
received a hollow fiber tube device with endogenous 
canine islets (as shown in Fig. 5); twelve dogs had an ini-
tial return of fasting blood glucose levels to normoglyce-
mia, and seven of those showed long-term normal fasting 
blood glucose levels (100–284  days) [18]. The eventual 
failure of the hybrid artificial pancreas device was attrib-
uted to loss of islet viability. Diabetic canine recipients of 
multiple (two) hollow fiber tube devices with endogenous 
islets were also evaluated via intravenous glucose toler-
ance tests (IVGTT). The dogs that received two devices 
showed even greater IVGTT results than the single 
device implantation group [18]. In another study, implan-
tation of the vascularized coiled hollow fiber tube device 
with allogeneic islets resulted in limited success; bovine 
and porcine islets implanted in pancreatomized dogs 
showed low islet viability and function (3–16 days) [18].
Another study was done involving nineteen human dia-
betic patients: a nylon-macrocapsule hollow tube device 
with fetal rabbit islets was implanted in the forearm cubi-
tal vein [20]. These implanted devices resulted in positive 
reversal of diabetes in fourteen of the patients for two 
years post-implantation, showing a 60–65 % decrease in 
exogenous insulin needed and a complete disappearance 
of hypo- or hyperglycemia related comas [20]. There was 
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some delay in neoangiogenesis which resulted in initial 
islet cell loss due to insufficient vascularization of the 
membrane for two weeks post-transplantation. Another 
possible concern for this intravascular device is the 
increased chance of thrombosis across the membrane, 
leading to decreased diffusion rates [18]. Thus, the use of 
anticoagulants is unadvisable in patients with this type of 
implant device due to increased bleeding risk.
The intravascular diffusion chamber has undergone 
revision and evolution resulting in another approach to 
Fig. 3 Schematic representation of alginate macrocapsule containing a monolayer of islets (top). Alginate macrocapsule with islets (bottom, left); 
Implantation of alginate macrocapsule into subcutaneous tissue of monkey (bottom, right). Reused with permission from [15]
Fig. 4 Intravascular hollow fiber tube diffusion chamber. Reused with permission from [19]
Page 5 of 11Hwang et al. Nano Convergence  (2016) 3:28 
engraftment: the ultra-filtration system, which eliminates 
any prolonged diffusion times for insulin, nutrients, and 
oxygen. This greater filtration, however, still has similar 
issues with clogging and thrombosis as the membrane, 
and can also be affected by buildup of proteins [19].
2.1.3  Current macroencapsulation application
2.1.3.1 Synthetic hydrogel Current applications of mac-
rocapsules are on the cutting edge of biomaterial tech-
nology. As opposed to the organic alginate hydrogel, 
synthetic hydrogels and thermoplastics have become 
more widely utilized for immunoisolation within mac-
roencapsulation devices, due to their controllable prop-
erties as a membranous barrier against the immune sys-
tem [21, 22].
Synthetic hydrogels function as a water infused net-
work of hydrophilic polymers or copolymers, which act 
as a membranous barrier for a macrocapsule device [23]. 
Due to their viscoelasticity and high H2O content, they 
mirror the attributes of natural biological tissues and 
usually elicit only a limited or no immune inflamma-
tory response [23]. The hydrogel’s structural integrity is 
built and dependent upon crosslinking between polymer 
chains. This crosslinking results in adjustable pore size, 
which is a desirable characteristic for selective immunoi-
solation [23].
Additional applications can be seen in thermoplastic 
membranes. Thermoplastic membranes are comprised 
of linear water insoluble chains, which can be configured 
into various forms through cyclic heating and cooling 
processes [11]. Thermoplastics provide greater chemi-
cal and mechanical stability compared to hydrogels [11]. 
However, hydrogels remain the most common material 
used for cell encapsulation because of the advantage in 
biocompatibility.
2.1.3.2 Inorganic membranes (Al/Al2O3, Si, Ti/
TiO2) Inorganic membranes for islet encapsulation 
have become another ongoing field of research. Three 
inorganic materials currently have desirable properties 
for the creation of immunoisolating membranes: silicon 
(Si), aluminum/aluminum oxide (Al/Al2O3) and titanium/
titanium oxide (Ti/TiO2) [24]. The use of these inorganic 
membranes as extravascular macrocapsule devices con-
fers several advantages over their polymer alternatives, 
such as a higher tolerance pore size distribution and more 
effective diffusion due to a decrease in membrane thick-
ness [25]. The use of an inorganic membrane composed of 
Al2O3 to encapsulate islets is also advantageous because it 
offers a uniform pore size and high pore density. However, 
the lack of biocompatibility is a disadvantage of inorganic 
membranes.
2.1.3.3 Microcontainer (epoxy‑polymer) Another pos-
sibility for macroencapsulation is a newly developed 
microcontainer composed of a nanoporous epoxy-based 
polymer [26]. The microcontainer device is produced 
through the use of adhesion layering techniques and 
offers several advantages over other macroencapsula-
tion devices, including a high degree of precision associ-
ated with the automated manufacturing process, greater 
durability, small size to prevent clumping, and the ability 
to determine islet viability in vivo via use of noninvasive 
procedures such as functional magnetic resonance imag-
ing [26]. There is, however, further testing and research 
needed in order to optimize the islet loading process, in 
addition to the need to determine the long-term function-
ality of the islets.
2.2  Microencapsulation of pancreatic islets
In microencapsulation, one or several islets are encap-
sulated within a hydrogel, and a number of these 
Fig. 5 Intravascular coiled hollow fiber tube within acrylic disc 
shaped housing. Reused with permission from [18]
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microcapsules are used for transplantation. Microencap-
sulation is used to enclose cells using hydrogels to form a 
polymer microcapsule ranging in size from zero to sev-
eral hundred micrometers, and first mentioned by Chang 
[27]. The benefits of microencapsulation over macroen-
capsulation include increased surface area, which pro-
motes increased diffusion, which is beneficial for cell 
oxygenation and glucose stimulated insulin release. How-
ever, there are disadvantages to microencapsulation, such 
as difficultly in retrieval after implantation [11]. Micro-
encapsulation uses various hydrogels composed of algi-
nate, agarose, polyethylene glycol (PEG) etc. to provide 
an immune barrier for the islets [11].
2.2.1  Microencapsulation using alginate
Alginate hydrogel is the most widely used material used 
for microencapsulation. Alginate microcapsules are 
made to contain islets through emulsification [28, 29]. 
Islets are suspended in the alginate/polymer blend; then, 
calcium ions are added, which force the material to emul-
sify around the islets [30]. Alginate microcapsules can be 
fabricated using a microdroplet generator by two-phase 
aqueous emulsification which can generate a thin algi-
nate hydrogel layer [31]. Optimization of the size of algi-
nate microcapsules is important for islet viability, surgical 
grafting risk, and metabolic or nutrient supplies. The alg-
inate microcapsule size can be controlled by adjustment 
of the physical and chemical parameters of the microdro-
plet generator [31].
When multiple islets are suspended in an alginate cap-
sule, they have been shown to clump together leading to 
necrosis of the islets in the center of the cluster due to 
hypoxia. This results in a reduction in the efficacy of the 
transplant. There is a need to ensure sufficient revascu-
larization and to minimize clumping while maintaining 
immune protection. Alginate is derived from seaweed 
and its molecular composition varies depending on the 
source. This inconsistency may lead to problems with 
biocompatibility and cytotoxicity. Slight variations in 
the alginate can lead to different degrees of permeability 
for insulin, immune cells, and cytokines. There is a large 
number of groups working on alginate microencapsu-
lation, but the animal studies, and especially the large 
animal studies, are rarely reproduced. Also, there is sig-
nificant loss in the number of transplantable microcap-
sules due to the variability in size [7].
The first case of microencapsulation of islets was in 
1980 when the Lim and Sun group encapsulated the 
islets in microcapsules composed of alginate-polylysine-
polyethyleneimine [32]. The results showed reversal of 
diabetes for 3  weeks in STZ-induced diabetic rats, but 
the results weren’t sustained due to poor biocompat-
ibility of the material. Later, in 1984, another group used 
alginate-polylysine-alginate  microcapsules to transplant 
islets in rats; this resulted in diabetes reversal for a year 
[33]. Further study in using alginate-polylysine-alginate 
showed that it did not cause a decrease in the insulin 
release in rat pancreatic islets [34]. In 1992, a study with 
purified alginate for islet encapsulation in dogs showed 
median insulin independence for insulin-dependent dogs 
[35]. Another study by the same group showed that algi-
nate microcapsules with sufficient beta cell mass were 
able to respond to increased blood glucose concentra-
tions without overshooting hypoglycemia [36]. A recent 
study showed long-term glycemic correction in rats using 
triazole-thiomorpholine dioxide alginate microcapsules. 
Glucose responsive mature beta cells that were derived 
from human embryonic stem cells were encapsulated in 
an alginate derivative and transplanted into STZ-induced 
diabetic rats. The results showed normoglycemia for 
174  days without immune suppression, at which point 
the implant was removed [37].
The first clinical case of human islet transplantation 
was reported by the Soon Shiong group in 1994 using 
high guluronic acid alginate microcapsules with human 
islets [38]. The results showed insulin independence 
9 months after the procedure, but the patient was on low-
dose immune suppressant drugs. Another group con-
ducted a clinical trial on two non-immune suppressed 
patients using alginate microcapsules that were double 
coated with poly-l-ornithine and sodium alginate. The 
patients showed improvement in their blood glucose lev-
els and a decrease in the daily insulin intake, but insulin 
independence was not achieved [28]. This study was later 
repeated in two more patients and showed similar results 
in 2011 [39]. These improvements were not permanent 
and the patients reverted to their insulin regimen at the 
end of the trials.
2.2.2  Microencapsulation using agarose
Another major material that has been used in micro-
encapsulation of islets is agarose. In agarose encapsula-
tion, islets are suspended in an agarose solution which 
is warmed to 40  °C and agitated to suspend the agarose 
solution in liquid paraffin. The agarose solution droplets 
are induced to gel by placing the tubes of solution on 
ice, encapsulating the islets within agarose beads (Fig. 6) 
[40]. The effects of the agarose encapsulation on islet sur-
vival were tested by implantation into STZ-induced dia-
betic mice and NOD mice. In the STZ-induced diabetic 
mice, normoglycemia was achieved for over 100  days. 
The NOD mice showed normal blood glucose levels for 
80–100 days [40]. The potential of immunoisolation was 
also tested for the prevention of autoimmune recurrence 
[41]. Islets were isolated from normal healthy mice and 
encapsulated into the agarose solution and transplanted 
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into NOD mice. The naked islet grafts as a control were 
destroyed, resulting in recurrence of diabetes in two 
weeks. However, the encapsulated islets showed nor-
moglycemia for 100  days. The microencapsulated islets 
showed that the beta cells were well-granulated and not 
infiltrated by immune cells, indicating that the encapsu-
lation was able to protect the cells from auto-immune 
destruction [41]. Another research was also done using 
agarose beads for islet xenotransplantation: hamster 
islets were transplanted into rats and the results showed 
normoglycemia for at least 100  days [42]. Based on the 
above results, agarose microencapsulation can provide 
complete protection against infiltration by immune cells 
as shown when implanted into NOD mice. In the future, 
agarose could have practical applications in humans if it 
is used to transplant insulin-producing cells made from 
induced pluripotent stem cells (iPS). In this case, there 
would be no immune rejection [7].
2.2.3  Microencapsulation using polyethylene glycol
Pancreatic islets have also been enclosed in microcap-
sules via interfacial photopolymerization of PEG-based 
macromeres. Microcapsules are formed when a dye in 
the cells is laser-excited, producing free radicals which 
trigger crosslinking. This crosslinking forms a PEG cap-
sule around the islets. By using different dyes and con-
centrations and changing the irradiation parameters, 
the thickness of the capsule can be idealized, typically 
to around 50  µm. This type of microcapsule is smaller 
than the others mentioned previously, thus reducing 
the injection volume. The very thin coatings created in 
interfacial photopolymerization are not very biodurable 
due to polymer instability and insufficient crosslinking. 
Recently, studies have been done researching the effects 
of crosslinking density and its effects on protein diffu-
sion; increased density delayed protein diffusion through 
the polymer membrane [43]. The lack of biodurability 
limits this method’s effectiveness in vivo because the cap-
sule structure may not maintain its integrity. The dyes 
used in the photopolymerization process also reduced 
the functionality of the beta cells as insulin secretion 
decreased significantly with increasing dye concentra-
tion [44]. Some studies have shown that PEG crosslinking 
can result in  >90  % islet viability and  >90  % encapsula-
tion efficiency. Recent studies have used microfluidics to 
create PEG capsules that have constant coating thickness 
instead of constant capsule diameter. This was shown to 
have the same functionality as normal islets, also pre-
venting loss of function during ex vivo culture [45].
In order to enhance the bioactive properties of the PEG, 
other peptides such as GLP-1 and ephrinA5-Fc have been 
immobilized along with PEG, improving the islet viability 
and functionality [46, 47]. The immobilization of bioactive 
GLP-1 within PEG hydrogels is efficient and does not alter 
the bulk hydrogel properties. Further, the GLP-1 immo-
bilized PEG hydrogels enhance the survival and insulin 
secretion of encapsulated islets.  Together with the cell-
adhesive peptide RGDS, the immobilized fusion proteins 
(EphA5-Fc and ephrinA5-Fc) synergistically increased the 
survival of both MIN6 β-cells and dissociated  islet  cells, 
both at a very low cell-packing density (<2  ×  106 cells/
mL) [46, 47]. Anti-Fas monoclonal antibodies have also 
been conjugated to the surface of PEG, providing a degree 
of immunoisolation: coatings containing anti-Fas anti-
body induced significant T cell apoptosis (21  ±  2  % of 
cells) after 24  h [48]. However, anti-Fas antibodies only 
provide protection against T cells and not the other types. 
In addition, to protect islets from cytokines such as TNF-
α, PEG can be functionalized with WP9QY, a peptide 
which inhibits the negative effects of TNF-α [49]. How-
ever, these methods may target a mechanism which is too 
specific to provide complete immune protection.
Fig. 6 Bioartifical membrane. The concept of immune isolation (left). Islet encpasulated in an agarose bead (right). Reused with permission from 
[40]
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2.2.4  Microencapsulation using peptide amphiphile
Pancreatic islets can be microencapsulated within a 
nanomatrix gel composed of peptide amphiphiles (PAs). 
PAs form an extracellular matrix (ECM)-mimicking 
environment to enhance islet viability without inhibit-
ing functionality while providing an immunoisolation 
environment. The PA consists of a hydrophilic peptide 
attached to a hydrophobic C16-carbon chain [50, 51]. The 
hydrophobic alkyl tails arrange into micelles which form 
long self-assembled nano scale fibers; then, at the correct 
pH and following the addition of calcium ions, the self-
assembled nanofibers form the nanomatrix gel [50–54]. 
The peptide sequence can be manipulated to possess vari-
ous properties of an ECM-mimicking environment such 
as cell adhesive ligands and enzyme mediated degrada-
tion, which enhances the bioactivity and biocompatibil-
ity of PAs [55–57]. The PA nanomatrix gel provides an 
islet-nurturing environment which improves islet viability 
and function [50, 58]. Furthermore, it provides a semi-
permeable barrier which prevents islet exposure to the 
immunocompetent cells while allowing oxygen, insulin, 
and nutrient transfer through the nanomatrix. PAs self-
assemble without chemical means, which indicates that 
there is a decreased risk for cytotoxicity stemming from 
toxic chemicals and dyes in the microcapsule. The chemi-
cal makeup of the PAs is carefully controlled during syn-
thesis, resulting in a low probability of potentially harmful 
material variation. Several studies have shown the ben-
eficial effects of PA nanomatrix gel encapsulation on 
islet viability and function. One study was conducted in 
which rodent islets were incorporated into the PA nano-
matrix gel containing a cell-adhesive ligand, arginine-
glycine-aspartic acid (RGD), as well as a MMP-2 sensitive 
sequence [50]. The PA-RGD nanomatrix gel-encapsulated 
islets maintained insulin secretion function and islet via-
bility over 14 days, while the unencapsulated islets showed 
a marked decrease in both function and viability (Fig. 7) 
[50]. In addition, another group developed a heparin-
binding PA nanomatrix gel, which enhanced angiogenic 
activity of the nanomatrix gel [58]. Delivery of FGF-2 and 
VEGF along with the heparin-binding PA nanomatrix gel 
demonstrated improved islet viability and function along 
with enhanced angiogenesis. For in vivo application of a 
PA nanomatrix gel, a bio-inspired hybrid nanosack was 
developed by combining a PA nanomatrix gel and an 
electrospun poly (ε-caprolactone) (ePCL) nanofiber sheet 
with porous crater-like structures [59]. The PA nanoma-
trix gel provides an islet-nurturing environment, while the 
ePCL nanofiber sheet maintains the mechanical stability 
of the gel within the implant area. In addition, the delivery 
of FGF-2 along with the crater-like structures of the ePCL 
nanofiber sheet synergistically benefited blood vessel for-
mation in the hybrid nanosack when implanted into the 
rat omentum. Thus, the hybrid nanosack shows potential 
to be used as a bioartifical pancreas since it provides an 
islet-protective and nurturing environment along with 
enhanced angiogenesis in the implantation area [59].
2.3  Surface modification of pancreatic islets
Surface modification is a form of immunoisolation that 
does not rely on microencapsulating islets, but rather 
on altering the surface of the islets themselves to form 
an immune barrier. A PEG complex may be covalently 
bound to the surface of the islets to provide a thin barrier 
to macrophages and reduce the release of cytokines. For 
example, a succinimidyl ester-functionalized PEG can 
react with amine groups present upon the cell surface of 
pancreatic islets to conceal host immunogenic surface 
antigens [60]. PEG was shown to very effectively block 
the effect of splenocytes, a type of macrophage. However, 
islets coated with PEG were shown to still be vulnerable 
to harmful cytokines like TNF-α [61]. This raises a sig-
nificant concern regarding surface modification. In fact, 
direct covalent surface modification can affect normal 
cellular functions which are associated with cell surface 
molecules [62]. It may be difficult to fully immunoiso-
late the islets from all of the macrophages and cytotoxic 
cytokines with such specific surface molecules. The 
strong covalent bond utilized in conjugation may also 
alter the physiology of the islet clusters. The insulin out-
put of modified islets was shown to be different over time 
compared with unmodified islets. The functionality of 
PEG surface-treated islets decreased even though most 
of the cells were still shown to be viable. After a longer 
period of surface modification, PEG may infiltrate and 
interact with the islets, causing necrosis [63].
As an alternative approach, an electrostatic adsorp-
tion has been proposed, in which poly(l-lysine)-graft-
poly(ethylene glycol) (PLL-g-PEG) copolymers were 
physically coated onto islet interfaces [64]. Although this 
approach can attain noncovalent surface modification of 
pancreatic islets, the inherent cytotoxicity of PLL polymers 
hampers the safety of this approach. To create a functional 
coating for improving response to glucose, a layer-by-layer 
(LbL) self-assembly technique has been studied. Wilson 
et al. formed nano-thin conformal coatings on individual 
pancreatic islets using LbL self-assembly of poly (l-lysine)-
g-poly(ethylene glycol)(biotin) and streptavidin (SA), and 
showed comparable functionality of the LbL-modified 
islets compared to non-coated controls in a murine model 
of allogeneic intraportal islet transplantation [65].
2.4  Bioartificial pancreas applications with microfluidic or 
micropatterning technology
According to the previous summary about immune protec-
tion for implanted islets, several types of biomaterials and 
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devices were fabricated using microfluidic or micropat-
terning technology. On the basis of the technical support, 
both microfluidic devices and micropatterned surfaces 
have been introduced to generate precise micro-scaled 
encapsulation in order to transfer islets and to protect 
islets against the body’s immune responses. For example, 
particles [45] and fibers [66, 67] for islet microencapsula-
tion were produced by the multiplexed droplet generating 
technique with microfluidic devices based on an oil–water 
interface. Moreover, islets were also encapsulated in an air–
water interface without using harmful immersion oil [68], 
using a hydrogel capsule as an effective nano- or micro-
scaled protection layer against inflammatory responses 
[69]. While generating hydrogel particles or fibers for islets 
has advantages in a multiplexed and rapid manufacturing 
process, they still have challenges for assembly into massive 
constructs to transplant. The total number of viable islets 
is one of the most important factors to recover the nor-
mal level of insulin secretion. However, islets can often be 
damaged during the fabrication process in a microfluidic 
device due to the high shear stress condition required for 
the droplet generation. Although the multiplexed genera-
tion of droplets can provide a large number of products at 
once, it is challenging to maintain high cellular viability. On 
the other hand, a micropatterning technique has provided a 
simple, precise approach for constructing a massive hydro-
gel structure at once, and for generating multicellular clus-
ters as islet-like cellular aggregates using single distributed 
islets or beta cells in highly packed array patterns [70–72]. 
Moreover, these kinds of approaches can also provide 
technically improved transplantable islets using not only 
restricted islets, but also differentiated stem cells or differ-
ent types of cells for co-culture, which can be alternative 
sources of islets for transplantation.
The development of microfluidic devices has largely 
switched to the multifunctional monitoring system for 
isolated islets [73–78]. The biological function of a sin-
gle islet inside a microfluidic device has been examined 
for intracellular Ca2+ [73, 75], amino acids [78], cellu-
lar impedance [77], or insulin secretion [74, 76] under 
dynamic external stimuli. Various designs of microfluidic 
devices enable the capture of an isolated islet in a micro-
fluidic channel and the analysis of their biofunctional 
metabolites, e.g. insulin secretion, Ca2+ influx, and apop-
totic factors based on the chemical gradient or dynamic 
culture conditions. Although technical improvement 
has been supported for real-time, accurate, and multi-
functional investigational methods using even a single 
islet, there is still a great need for an intensive microflu-
idic device to assess the immune response from bare or 
encapsulated islets and to assist in pretreatment of islets 
before transplantation. Although many groups have 
attempted to encapsulate islets for protection against 
inflammatory responses, producing the outer structure 
as a carrier, the inner structure of the islets has been 
overlooked. For instance, flow-induced culture condi-
tions were applied to islets by Sankar et al. [79] and dem-
onstrated the importance of microvascularization inside 
Fig. 7 Pancreatic islet encapsulation with PA nanomatrix gel. a Scheme of islet encapsulation. b–e Insulin producing beta cell staining and islet 
viability test after 14 days of islet culture. Dithizone staining of (b) bare islets and (c) PA encapsulated islets. Live/dead staining of (d) bare islets and 
(e) PA encapsulated islets. In b and c, red shows insulin producing beta cells. In d and e, live cells are stained green, and dead cells are stained red. 
Reused with permission from [50]
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the isolated islets. Without the microsvaculature within 
the islets, it is difficult to maintain or sustain isolated 
islets for more than a few weeks. It is critical not only for 
intercellular restoration of restricted diffusion in  vitro, 
but also for longer maintenance of ex  vivo islets within 
flow-induced culture conditions. The encapsulated islets 
could be exposed to physiological flow conditions as a 
pretreatment process in order to stabilize the islets prop-
erly before transplant.
3  Conclusions
A bioartificial pancreas is a therapeutic approach to 
enable immunoisolation of transplanted islets, which 
allows allo- and xenotransplantation of islets without or 
with minimal immune suppression. In this review, we 
have discussed various types of bioartificial pancreases 
including macro- and microencapsulation and islet sur-
face modification; each strategy has some advantages 
and limitations. Macroencapsulation approach is use-
ful for enclosing islets with relative ease of retrieval if 
necessary. However, there is a concern for clumping of 
the islets, which could potentially reduce oxygen and 
nutrient flow to the cells on the interior of the clus-
ter. Microencapsulation approach is recently the most 
widely utilized strategy to encapsulate single or several 
islets, because it is favorable for substance exchange due 
to its large surface area. However, microencapsulated 
islets are hardly retrievable once implanted into the 
body, and the size or thickness of the gel and the per-
meability should be optimized for this application. Sur-
face modification approach enables the generation of a 
very thin and finely-controlled immune barrier coating 
against the host immune system, but it may alter the 
physiology of the islets during the modification process 
and the coating stability should also be improved for 
long-term islet transplantation. From a technical point 
of view, microfluidic or micropatterning technology 
enables the development of various tools in bioartificial 
pancreas application, such as rapid, precise, multiplexed 
fabrication of nano- and micro-sized encapsulation of 
transplantable islets using various materials and com-
positions. Although previous technical development of 
microfluidic devices has been more focused on in vitro 
monitoring systems, they may also have great technical 
potential for encapsulating and transferring islets in the 
bioartificial pancreas.
In interest of future applications of pancreatic islet 
transplantation, recent advances in the developmen-
tal biology of pancreatic organogenesis have enabled 
researchers to attempt the generation of fully differenti-
ated pancreatic beta cells from embryonic stem cells or 
iPSCs; a bioartificial pancreas may also provide great 
potential for the transplantation of stem cell-derived 
beta cells. Despite much progress in the development of 
the bioartificial pancreas, its clinical applications are few 
and the clinical outcomes are not clear. Therefore, much 
effort is still needed to overcome the limitations of bioar-
tificial pancreas applications.
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